| 85 | 5 | 129 |
| 下载次数 | 被引频次 | 阅读次数 |
为研究替莫唑胺联合放疗对胶质瘤患者血管内皮生长因子(VEGF)、白介素-8(IL-8)表达的影响,本研究选取2010年7月至2011年6月我院收治的60例胶质瘤患者,根据随机抽签法分为试验组和对照组,每组30例。对照组使用放疗方式,试验组患者在此基础上口服替莫唑胺,150 mg·m-2·d-1,连续服用5 d,4周为1个治疗周期,根据患者具体情况给药46个周期。比较两组患者治疗前后VEGF、IL-8水平、生活质量改善情况,评判两组患者的临床疗效、生存率、不良反应。结果显示,治疗后,试验组的总有效率86.67%(26/30)显著高于对照组63.33%(19/30),差异有统计学意义(p<0.05)。试验组的VEGF、IL-8水平显著低于对照组,(65.93±3.55)pg/m L比(85.85±3.26)pg/m L,(20.81±1.92)pg/m L比(31.11±3.10)pg/m L(p<0.05);试验组的KPS评分明显高于对照组,(83.06±5.16)分比(71.34±2.82)分(p<0.05);试验组1年、2年、3年的生存率显著高于对照组,90.00%(27/30)比73.33%(22/30),80.00%(24/30)比50.00%(15/30),66.67%(20/30)比36.67%(11/30);中位复发时间晚于对照组,(24.32±2.32)月比(16.23±1.45)月,差异均有统计学意义(p<0.05);试验组和对照组的不良反应率比较无显著性差异,16.67%(5/30)比20.00%(6/30)(p>0.05)。研究结果表明替莫唑胺联合放疗能明显降低胶质瘤患者VEGF、IL-8表达,临床疗效良好,可提高患者的生活质量和生存率,安全性高。
Abstract：To study the influences of temozolomide combined with radiation therapy in vascular endothelial growth factor(VEGF) and interleukin-8(IL-8) expressions of glioma patients. 60 cases of patients with glioma in our hospital from July 2010 to June 2011 were selected, they were divided into treatment group and control group according to the random draw method, 30 cases in each group. The control group were given radiotherapy method,while the treatment group were given emozolomide on the basis of the control group, 150 mg·m-2·d-1, for 5 d, 4weeks for a treatment cycle, according to the specific situation of the patients for 46 cycles. the VEGF, IL-8levels before and after treatment, quality of life improvement of the two groups were compared, the curative effects, survival rates, adverse reactions of two groups were judged. After treatment, the total effective rate of the treatment group 86.67%(26/30) was significantly higher than the control group 63.33%(19/30), the difference was statistically significant(p<0.05). The VEGF, IL-8 levels of the treatment group significantly lower than the control group(65.93±3.55) pg/m L vs(85.85±3.26) pg/m L,(20.81±1.92) pg/m L vs(31.11±3.10) pg/m L(p<0.05). The KPS score of the treatment group was obviously higher than the control group(83.06±5.16) points vs(71.34±2.82) points(p <0.05). The 1st, 2nd, 3rdyear survival rate of the treatment group was significantly higher than the control group90.00%(27/30) vs 73.33%(22/30), 80.00%(24/30) vs 50.00%(15/30), 66.67%(20/30) vs 36.67%(11/30), and the median time to relapse was later than the control group(24.32±2.32) months than(16.23±1.45) months, the differences were statistically significant(p<0.05). The difference of adverse reaction rates between treatment group and control group was not significant 16.67%(5/30) vs 20.00%(6/30)(p<0.05). The results proved that temozolomide combined with radiotherapy can obviously reduce the VEGF, IL-8 expressions of patients with glioma, the clinical curative effect is good, it can improve the life quality and survival rate, and has higher safety.
Chen W.F.,Wu Q.L.,and Mo L.G.,2014,Three dimensional conformal radiotherapy concurrent combined with temozolomide treatment for postoperative high grade glioma:a meta analysis,Zhonghua Zhongliu Fangzhi Zazhi(Chinese Journal of Cancer Prevention and Treatment),21(7):543-551(陈卫峰,吴倩岚,莫立根,2014,高级别脑胶质瘤术后3D-CRT与替莫唑胺同步放化疗Meta分析,中华肿瘤防治杂志,21(7):543-551)
Chen Y.P.,Zhang N.,Ding Z.M.,and Xia Z.B.,2012,The inhibitory effect of combined Aurora A gone knockdown and Tomozolomide on growth of U87 glioma cells in vitro,Zhongguo Shenjing Jingshen Jibing Zazhi(Chinese Journal of Nervous and Mental Diseases),38(5):284-288(陈云鹏,张弩,丁之明,夏之柏,2012,敲低Aurora A基因增强替莫唑胺抗人脑胶质瘤U87细胞的作用,中国神经精神疾病杂志,38(5):284-288)
Cho M.,Joo J.D.,Kim B.H.,Choe G.,and Kim C.Y.,2016,Hypothalamic extraventricular neurocytoma(EVN)in a pediatric patient:a case of EVN treated with subtotal removal followed by adjuvant radiotherapy,Brain Tumor Research and Treatment,4(1):35-39
Cortese K.,Daga A.,Monticone M.,Tavella S.,Stefanelli A.,Aiello C.,Bisio A.,Bellese G.,and Castaqnola P.,2016,Carnosic acid induces proteasomal degradation of Cyclin B1,RB and SOX2 along with cell growth arrest and apoptosis in GBM cells,Phytomedicine,23(7):679-685
Ghasemi A.,Fallah S.,and Ansari M.,2016,Mi R-153 as a Tumor suppressor in glioblastoma multiforme is downregulated by DNA methylation,Clin.Lab.,62(4):573-580
Ishikawa E.,and Yamamoto T.,2016,Intraoperative BCNUwafer implantation for high-grade glioma-A questionnaire targeting Japanese Neurosurgeons,Gan To Kagaku Ryoho,43(5):603-607
Kaufhold S.,Garbán H.,and Bonavida B.,2016,Yin Yang 1 is associated with cancer stem cell transcription factors(SOX2,OCT4,BMI1)and clinical implication,Journal of Experimental&Clinical Cancer Research,35(1):84
Kim J.W.,Auffinger B.,Spencer D.A.,Miska J.,Chang A.L.,Kane J.R.,Young J.S.,Knojia D.,Qiao J.,Mann J.F.,Zhang L.,Wu M.,Ahmed A.U.,Aboody K.S.,Strong T.V.,Hébert C.D.,and Lesniak M.S.,2016,Single dose GLP toxicity and biodistribution study of a conditionally replicative adenovirus vector,CRAd-S-pk7,administered by intracerebral injection to Syrian hamsters,Journal of Translational Medicine,14(1):134
Lee J.,Cho J.,Chang J.H.,and Suh C.,2016,Re-Irradiation for recurrent gliomas:treatment outcomes and prognostic factors,Yonsei Medicine Journal,57(4):824-830
Li Y.,Gao Y.L.,Liu G.,Zhou X.D.,Wang Y.,Wang Y.L.,and Ma L.,2014,Intranasal administration of temozolomide for brain-targeting delivery:therpeutic effect on glioma in rats,Nanfang Yike Daxue Xuebao(Journal of Southern Medical University),34(5):631-635(李颖,高永良,刘刚,周绣棣,王岩,王玉林,马林,2014,经鼻腔给药的替莫唑胺脑靶向制剂对大鼠胶质瘤的治疗效果,南方医科大学学报,34(5):631-635)
Liu W.,Wang C.K.,and Zhi D.S.,2012,Expressions of MMP-2,MMP-9,VEGF,Flk-1 and P16 in glioma invasive tissues and their clinical significances,Jilin Daxue Xuebao(Journal of Jilin University:Med.Ed.),38(4):770-774(刘伟,王长坤,只达石,2012,胶质瘤浸润组织中MMP-2,MMP-9,VEGF,Flk-1和P16的表达及其临床意义,吉林大学学报(医学版),38(4):770-774)
Lu Z.P.,Cheng Z.P.,Chong Q.,Chen J.X.,and Mo Y.,2013,Therapeutic applications on temozolomide combined with radiotherapy in treatment of malignant glioma,Chongqing Yixue(Chongqing Medicial Journal),42(11):1248-1249(卢志平,程金建,宠强,陈甲信,莫颖,2013,替莫唑胺联合放疗在恶性胶质瘤患者中的治疗应用,重庆医学,42(11):1248-1249)
Mao D.Q.,Pan L.,Dai Q.B.,Lou S.L.,Cheng J.,Ruan J.,Chen X.,and Hu C.L.,2013,Observation on the short-term clinical efficacy and safety postoperative radiotherapy combined with temozolomide in treatment for high-grade gliomas,Chongqing Yixue(Chongqing Medical Journal),42(1):21-23(毛德强,潘玲,戴勤弼,娄四龙,陈杰,阮建,程兴,胡重玲,2013,术后放疗联合替莫唑胺治疗高级别胶质瘤的近期临床疗效及安全性观察,重庆医学,42(1):21-23)
Pradhan M.B.,Pathak S.,Mathur D.,and Ladiwala U.,2016,Optically trapping tumor cells to assess differentiation and prognosis of cancers,Biomedical Optics Express,7(3):943-948
Qi L.,Jin H.,Li Y.Q.,Yu H.Q.,Wen N.,Liu W.,and Liu J.X.,2013,Effect of schisandrin B on expression of vascular endothelial growth factor in glioma SHG-44 cells and its inhibitory effect on cell growth,Jilin Daxue Xuebao(Journal of Jilin University:Med.Ed.),39(1):1-4(齐玲,金宏,李蕴潜,于洪泉,温娜,刘威,刘兴吉,2013,五味子乙素对脑胶质瘤SHG-44细胞VEGF表达水平的影响及其细胞生长抑制作用,吉林大学学报(医学版),39(1):1-4)
Ropper A.E.,Zeng X.,Haragopal H.,Anderson J.E.,Aljuboori Z.,Han I.,Abd-El-Barr M.,Lee H.J.,Sidman R.L.,Snyder E.Y.,Viapiano M.S.,Kim S.U.,Chi J.H.,and Teng Y.D.,2015,Targeted treatment of experimental spinal cord glioma with dual gene-engineered human neural stem cells,Neurosurgery,79(3):481-491
Wang Y.W.,Yin C.L.,Zhang Z.Y.,Zhang H.Y.,Zhang K.,Zhang Z.M.,and Liao H.,2012,Meta-analysis for temozolomide for high grade gliomas,Shandong Daxue Xuebao(Journal of Shandong University)(Health Science),50(6):80-82(王耀伍,尹春丽,张志勇,张宏义,张坤,张志民,廖珩,2012,替莫唑胺对高级别脑胶质瘤疗效的Meta分析,山东大学学报(医学版),50(6):80-82)
Wang Z.H.,Wang J.H.,Guo X.Q.,Yang L.Q.,and Wu L.P.,2013,Efficacy and safety of intensity modulated radiation therapy combined with temozolomide for gradeⅢ-Ⅳglioma patients with postoperative residual,Zhongguo Quanke Yixue(Chinese General Practice),16(33):3962-3964(王振华,王建华,郭小奇,杨留勤,武莉萍,2013,调强放疗联合替莫唑胺胶囊治疗成人Ⅲ-Ⅳ级胶质瘤术后残留临床疗效观察,中国全科医学,16(33):3962-3964)
Wu X.H.,Zhu X.X.,Shen Z.T.,Li B.,Shen J.S.,and Gao S.P.,2012,Efficacy of temozolomide in treating recurrent malignant glioma,Jiangsu Yiyao(Jiangsu Medical Journal),38(7):788-790(武新虎,朱锡旭,沈泽天,李兵,沈君姝,高淑萍,2012,替莫唑胺治疗复发性恶性脑胶质瘤疗效,江苏医药,38(7):788-790)
Xiang G.B.,Deng Y.,Bao F.,Jiang X.F.,Wu X.W.,Li H.S.,Cheng L.R.,and Han H.,2013,Clinical observation of PCFand FOLFOX4 in treating intermediate and advanced gastric cancer,Anhui Yike Daxue Xuebao(Acta Universitatis Medicinalis Anhui),8(7):810-813(项高波,邓勇,鲍风,江幸福,吴习威,李欢松,程立仁,韩辉,2013,IL-24与VEGF在脑胶质瘤中的表达以及与肿瘤微血管密度的关系,安徽医科大学学报,8(7):810-813)
Yang X.N.,and Wu Y.L.,2004,RECIST-New guidelines to evaluate the response to treatment in solid tumors,Xunzheng Yixue(The Journal of Evidence-based medicine),4(2):85-90(杨学宁,吴一龙,2004,实体瘤治疗疗效评价标准-RE-CIST,循证医学,4(2):85-90)
Yao J.,Qi H.X.,Fan X.Y.,Ni S.L.,Wang J.G.,and Li X.G.,2012,Controlled release system delivering temozolomide fir treatment of experimental glioma in vitro,Shandong Daxue Xuebao(Journal of Shandong University)(Health Science),50(9):6-10(姚军,齐宏旭,范晓勇,倪石磊,王建刚,李新刚,2012,替莫唑胺缓释系统的构建及体外抗胶质瘤细胞的实验研究,山东大学学报(医学版),50(9):6-10)
Zeng R.,Kuanng J.G.,Deng S.G.,Xia L.,Deng S.Z.,Xu J.,Yang Q.X.,and Gong M.T.,2013,Expressions of p53,p15 and VEGF in human brain glioma and their relationship with malignance degree,Xi'an Jiaotong Daxue Xuebao(Journal of Xi'an Jiaotong University:Medical Science),34(3):366-370(曾冉,况建国,邓世钢,夏亮,邓圣泽,徐奖,杨全喜,公茂田,2013,人脑胶质瘤p53,p15,VEGF的表达及与恶性程度的相关分析,西安交通大学学报(医学版),34(3):366-370)
Zhang Y.Y.,Qu Y.Q.,Jiang X.,Zhao X.,Guo X.,and Feng Q.,2012,Evaluation of short-term efficacy and saftety of intensity modulated radiation therapy plus concomitan and adjuvant temozollomide in patients with malignant gliomas,Jilin Daxue Xuebao(Journal of Jilin University:Med.Ed.),38(3):571-574(张玉宇,曲雅勤,姜新,赵欣,郭潇,冯奇,2012,调强适形放射治疗联合替莫唑胺化疗治疗恶性脑胶质瘤的近期疗效及安全性评价,吉林大学学报(医学版),38(3):571-574)
基本信息:
DOI：10.13417/j.gab.035.003285
中图分类号:R739.41
引用信息:
[1]蒲波,高晋健.替莫唑胺联合放疗对胶质瘤患者VEGF、IL-8表达的影响[J].基因组学与应用生物学,2016,35(12):3285-3291.DOI:10.13417/j.gab.035.003285.
基金信息:
四川省科技厅基金(2011F20032)资助
2016-12-25
2016-12-25